Recruiting

PRP

Sponsor:

University of Utah

Code:

NCT07231471

Conditions

Osteoarthritis (OA)

Osteoarthritis (OA) of the Knee

Osteoarthritis (OA) of the Hip

Osteoarthritis (OA) of the Shoulder

Osteoarthritis Ankle

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Platelet Rich Plasma Injection

Platelet Rich Plasma Preparation

Study Details

Brief summary:

The primary purpose of this study is to follow patients with various musculoskeletal (MSK) conditions over a one-year follow-up period after receiving a platelet rich plasma (PRP) injection, assessing changes in their pain levels, functional abilities, and overall patient satisfaction.

This will develop a robust registry of patients treated with PRP for a range of MSK conditions. These conditions include, but are not limited to, osteoarthritis (OA) of the knee, hip, glenohumeral joint, elbow, ankle, and sacroiliac joint, as well as rotator cuff tendinopathy, lateral and medial epicondylitis, plantar fasciitis, patellar tendinopathy, Achilles tendinopathy, and proximal hamstring tendinopathy.

Conditions

Osteoarthritis (OA)

Osteoarthritis (OA) of the Knee

Osteoarthritis (OA) of the Hip

Osteoarthritis (OA) of the Shoulder

Osteoarthritis Ankle

Study ID

NCT07231471

Start date

Dec 29, 2025

Status verified date

Mar, 2026

Completion date

Jan 1, 2035

Anticipated

Primary completion date

Jan 1, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • 18+ years old
  • Musculoskeletal pathology that may benefit from a PRP injection
  • Failed other conservative treatments

Exclusion Criteria:

  • No active malignancy
  • No active infection in the area of injection
  • No platelet disorder
  • No active systemic infections
  • No patients currently undergoing dialysis

Study Design

Enrollment

10000 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Platelet Rich Plasma Injection

Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their whole blood and the produced PRP will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months..

Interventions

Platelet Rich Plasma Injection

Participants who are eligible and provide consent to participate will undergo a Platelet-Rich Plasma (PRP) injection. Their blood will be analyzed using a cell counter, and they will be asked to complete follow-up surveys at 2 weeks, 6 weeks, 3 months, 6 months, and 12 months.

Platelet Rich Plasma Preparation

The patient's blood is collected into syringes. That blood is spun in a centrifuge at high speeds, which separates their blood into layers (red blood cells, white blood cells, and plasma). The plasma portion, which contains the platelets, is transferred to a different syringe for later injection. In some cases, the plasma is spun in the centrifuge again (a "double spin" technique) to further concentrate the platelets in the plasma. The patient's blood is not exposed to air, and it is transferred by tubing between syringes with a Luer Lock connection.

Primary outcome measure

  • Visual analog score (pain) [ Time Frame: 6 months ]

Central Contacts and Locations

Central contacts

Christina Geisler, MS

18012133379christina.geisler@utah.edu

Jamie Egbert, MS

jamie.egbert@utah.edu

Locations

University of Utah Orthoaedic Center

Recruiting

Salt Lake City, Utah, United States, 84111-1334

Contacts

Luke Johnson, BS

8012133379luke.a.johnson@hsc.utah.edu

Principal Investigator:

Daniel Cushman, MD

More Information

Sponsor

University of Utah

Last update posted

May 6, 2026

Last verified

Mar, 2026

Keywords

  • PRP
  • Platelet Rich Plasma
  • Osteoarthritis
  • Tendinopathy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Utah on 2026-05-06.